What Affinity Asset Advisors, LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1773195 · Filed Nov 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
ISHARES TRRUSSELL 2000 ETFPut option | 1M | New | $277.9M | 11.3% |
ROIVRoivant Sciences Ltd. | 3.2M | −14.7% | $117M | 4.8% |
| 1.3M |
| ±0% |
| $113.9M |
| 4.6% |
SPDR SERIES TRUSTST STR SP BIOTPut option | 600K | New | $94.6M | 3.8% |
ERASErasca, Inc. | 5.6M | +6.5% | $82M | 3.3% |
TRAXFirst Tracks Biotherapeutics, Inc. | 2.1M | +2.4% | $73.7M | 3% |
XENEXenon Pharmaceuticals Inc. | 1.9M | +19.1% | $70.7M | 2.9% |
INSMInsmed Inc | 564.3K | −13.2% | $64.4M | 2.6% |
ALKSAlkermes plc. | 1.6M | +39.1% | $63.4M | 2.6% |
| 325K | −35.0% | $62.6M | 2.5% |
ARK ETF TRGENOMIC REV ETFPut option | 1M | New | $54.2M | 2.2% |
ARK ETF TRGENOMIC REV ETFCall option | 950K | +26.7% | $51.5M | 2.1% |
ORKAOruka Therapeutics, Inc. | 600K | +1.7% | $50M | 2% |
AVTXAvalo Therapeutics, Inc. | 3.2M | +11.9% | $49.7M | 2% |
CYTKCytokinetics Inc | 750K | +36.4% | $49.4M | 2% |
| 250K | −47.4% | $48.1M | 2% |
RVMDRevolution Medicines, Inc. | 225K | −10.0% | $46.2M | 1.9% |
PRAXPraxis Precision Medicines, Inc. | 155K | −16.2% | $45.1M | 1.8% |
BLTEBelite Bio, Inc | 242.1K | +46.7% | $41.1M | 1.7% |
| 4.3M | New | $40.7M | 1.7% |
CLDXCelldex Therapeutics, Inc. | 1.2M | +65.8% | $37.6M | 1.5% |
ABVXAbivax S.A. | 330K | ±0% | $32.7M | 1.3% |
DNTHDianthus Therapeutics, Inc. | 350K | −12.5% | $30.8M | 1.3% |
| 1.7M | New | $28.7M | 1.2% |
ODTXOdyssey Therapeutics, Inc. | 1.3M | +64.4% | $28M | 1.1% |
ARWRArrowhead Pharmaceuticals, Inc. | 425K | +183.3% | $27.8M | 1.1% |
TRVITrevi Therapeutics, Inc. | 1.8M | ±0% | $25.8M | 1% |
OVIDOvid Therapeutics Inc. | 10.1M | ±0% | $25.3M | 1% |
SGMTSagimet Biosciences Inc. | 2.5M | +1.2% | $25M | 1% |
| 615.4K | +146.2% | $24.9M | 1% |
LXEOLexeo Therapeutics, Inc. | 7.2M | +24.8% | $24.5M | 1% |
PTGXProtagonist Therapeutics, Inc | 172.1K | ±0% | $24.3M | 1% |
NRIXNurix Therapeutics, Inc. | 967.6K | ±0% | $22.9M | 0.9% |
OMEROS CORPNOTE 9.500% 6/1 | 6.5M | ±0% | $21.2M | 0.9% |
VOGXVogenx, Inc. | 915K | New | $20.9M | 0.8% |
MLYSMineralys Therapeutics, Inc. | 750K | ±0% | $18.8M | 0.8% |
TYRATyra Biosciences, Inc. | 850K | +325.0% | $18.6M | 0.8% |
STROSutro Biopharma, Inc. | 1.2M | −1.7% | $18.6M | 0.8% |
TVTXTravere Therapeutics, Inc. | 300K | ±0% | $17.7M | 0.7% |
ANROAlto Neuroscience, Inc. | 643.3K | −24.3% | $16.4M | 0.7% |
ARVNArvinas, Inc. | 2.1M | New | $15.9M | 0.6% |
EPRXEupraxia Pharmaceuticals Inc. | 1.7M | +4.0% | $15.6M | 0.6% |
RLAYRelay Therapeutics, Inc. | 850K | −19.0% | $15.3M | 0.6% |
MDGLMadrigal Pharmaceuticals, Inc. | 30K | −25.0% | $15.1M | 0.6% |
CGEMCullinan Therapeutics, Inc. | 875.8K | ±0% | $13.4M | 0.5% |
SVRASavara Inc | 2.5M | ±0% | $13M | 0.5% |
COAGHemab Therapeutics Holdings, Inc. | 420K | +204.3% | $13M | 0.5% |
COGENT BIOSCIENCES INCNOTE 1.625%11/1 | 11M | ±0% | $12.1M | 0.5% |
CLYMClimb Bio, Inc. | 972K | ±0% | $11.1M | 0.5% |
IBRXImmunityBio, Inc. | 1.2M | New | $11.1M | 0.5% |
BEAMBeam Therapeutics Inc. | 450K | New | $11M | 0.4% |
CATXPerspective Therapeutics, Inc. | 4M | −5.4% | $11M | 0.4% |
JBIOJade Biosciences, Inc. | 760.4K | −9.5% | $10.7M | 0.4% |
PRLDPrelude Therapeutics Inc | 2.6M | New | $10.2M | 0.4% |
CRSPCRISPR Therapeutics AG | 175K | +75.0% | $9.7M | 0.4% |
MANEVeradermics, Inc | 79.4K | −20.6% | $9.6M | 0.4% |
ESTAEstablishment Labs Holdings Inc. | 149.8K | +1.2% | $9.6M | 0.4% |
AMLXAmylyx Pharmaceuticals, Inc. | 300K | +203.0% | $8.7M | 0.4% |
KRSAKorsana Biosciences, Inc. | 263.1K | New | $8.4M | 0.3% |
PRQRProQR Therapeutics N.V. | 5M | −10.4% | $8.3M | 0.3% |
VERAVera Therapeutics, Inc. | 250K | ±0% | $8.1M | 0.3% |
DMRADamora Therapeutics, Inc. | 375K | New | $8M | 0.3% |
RACCResearch Alliance Corp III | 735.5K | +98.8% | $8M | 0.3% |
SLGLSol-Gel Technologies Ltd. | 105K | +23.7% | $7.8M | 0.3% |
CELCUITY INCNOTE 0.250% 8/0 | 8M | +300.0% | $7.8M | 0.3% |
IDYAIDEAYA Biosciences, Inc. | 200K | −50.0% | $7.7M | 0.3% |
AVRAnteris Technologies Global Corp. | 912.4K | ±0% | $7.1M | 0.3% |
AKTSAktis Oncology, Inc. | 350K | New | $6.8M | 0.3% |
ELVNEnliven Therapeutics, Inc. | 148K | −70.4% | $6.8M | 0.3% |
NAMSNewAmsterdam Pharma Co N.V. | 275K | ±0% | $6.7M | 0.3% |
HLXCHelix Acquisition Corp. III | 625K | −50.0% | $6.6M | 0.3% |
XFORX4 Pharmaceuticals, Inc | 2.1M | +1,322.4% | $6M | 0.2% |
| 353.1K | New | $5.3M | 0.2% |
KRROKorro Bio, Inc. | 531.9K | −24.8% | $5.3M | 0.2% |
VRDNViridian Therapeutics, Inc.DE | 250K | ±0% | $5.1M | 0.2% |
SLNSilence Therapeutics plc | 450K | New | $4.9M | 0.2% |
IBIOiBio, Inc. | 4.1M | +3.1% | $4.9M | 0.2% |
TSHATaysha Gene Therapies, Inc. | 1M | −42.9% | $4.9M | 0.2% |
SABSSAB Biotherapeutics, Inc. | 1.5M | ±0% | $4.8M | 0.2% |
IRDOpus Genetics, Inc. | 900K | New | $4.4M | 0.2% |
FTHFaeth Therapeutics, Inc. | 144.4K | ±0% | $4.3M | 0.2% |
EQEquillium, Inc. | 2.6M | −36.2% | $4.2M | 0.2% |
NTLAIntellia Therapeutics, Inc. | 350K | New | $4.2M | 0.2% |
LTGOLatigo Biotherapeutics, Inc. | 250K | New | $4.2M | 0.2% |
RZLTRezolute, Inc. | 1M | ±0% | $4.1M | 0.2% |
ARK ETF TRGENOMIC REV ETF | 74.9K | New | $4.1M | 0.2% |
DTILPrecision Biosciences Inc | 646.6K | ±0% | $4M | 0.2% |
AMANAmanat Acquisition Corp. | 375K | ±0% | $4M | 0.2% |
| 250K | New | $3.8M | 0.2% |
CMPSCOMPASS Pathways plc | 301.2K | ±0% | $3.7M | 0.2% |
RNAQURainier Acquisition Corp | 365K | New | $3.7M | 0.2% |
MGNXMacrogenics Inc | 954K | −21.6% | $3.7M | 0.1% |
RACDResearch Alliance Corp IV | 300K | New | $3.6M | 0.1% |
IMVTImmunovant, Inc. | 100K | ±0% | $3.4M | 0.1% |
ANABAnaptysbio, Inc | 66.5K | −92.0% | $3.3M | 0.1% |
ZURAZura Bio Ltd | 800K | −45.4% | $3.3M | 0.1% |
NAMSWNewAmsterdam Pharma Co N.V. | 245K | ±0% | $3.3M | 0.1% |
VRCAVerrica Pharmaceuticals Inc. | 688.7K | −2.6% | $3.3M | 0.1% |
AVBPArriVent BioPharma, Inc. | 100K | −20.0% | $3M | 0.1% |
MBXMBX Biosciences, Inc. | 50K | −33.3% | $2.9M | 0.1% |
PMVPPMV Pharmaceuticals, Inc. | 1.8M | New | $2.9M | 0.1% |
SLDBSolid Biosciences Inc. | 400K | New | $2.9M | 0.1% |
OACCUOaktree Acquisition Corp. III Life Sciences | 250K | ±0% | $2.7M | 0.1% |
ENTXEntera Bio Ltd. | 934.4K | New | $2.7M | 0.1% |
NMRANeumora Therapeutics, Inc. | 4.5M | +320.3% | $2.7M | 0.1% |
TCGXTCGX Acquisition Corp. | 200K | New | $2.5M | 0.1% |
ANLAdlai Nortye Group Ltd. | 153.8K | ±0% | $2.5M | 0.1% |
EIKNEikon Therapeutics, Inc. | 298K | +204.1% | $2.4M | 0.1% |
| 250K | New | $2.4M | 0.1% |
JTTTJATT III Acquisition Corp | 212K | New | $2.3M | 0.1% |
JATTJATT II Acquisition Corp. | 200K | ±0% | $2.2M | 0.1% |
SPROSpero Therapeutics, Inc. | 1.3M | New | $1.6M | 0.1% |
GENBGenerate Biomedicines, Inc. | 100K | −75.0% | $1.5M | 0.1% |
NXTCNextCure, Inc. | 292K | +595.8% | $1.5M | 0.1% |
LENZLENZ Therapeutics, Inc. | 300K | +200.0% | $1.2M | 0.1% |
JSPRJasper Therapeutics, Inc. | 1.9M | New | $1.1M | 0.1% |
FDMT4D Molecular Therapeutics, Inc. | 50K | New | $715.5K | 0.1% |
SLSSELLAS Life Sciences Group, Inc. | 50K | New | $615.5K | 0.1% |
ENTAEnanta Pharmaceuticals Inc | 29.3K | New | $386.2K | 0.1% |
QTTBQ32 Bio Inc. | 27.8K | ±0% | $229.7K | 0.1% |
ADGMAdagio Medical Holdings, Inc. | 80K | ±0% | $12.2K | 0.1% |